Quick answer: Buy and bill is the process where a specialty practice purchases medication directly from a distributor, administers it to the patient, and then bills the payer for reimbursement. It gives the practice control over the drug supply chain and over which product goes into the patient. Buy and bill covers provider-administered drugs only, which is why it sits at the center of any in-office infusion program: the infusion is how you deliver the therapy, and buy and bill is how you acquire and get paid for the drug.
Buy and bill is a drug acquisition and reimbursement model used across outpatient specialty settings. Hospital outpatient clinics usually receive specialty products, including injectables, biologicals, IVIG and immunoglobulins, through a hospital pharmacy. Independent physician practices buy the drug directly from a specialty distributor and bill the payer after administration.
The mechanics are simple. The practice purchases the drug, stores it until the patient's appointment, administers it, and then submits a claim to a third-party payer. The name comes from those two steps: the provider buys the drug, then bills for it. The practice also bills separately for the administration service under the relevant injection or infusion CPT codes.
What makes the model attractive is not the billing sequence. It is that nobody else touches the drug. The practice purchases, stores, and administers, which means the practice can vouch for the product's pedigree, its storage conditions, and its identity at the moment it goes into the patient.
Buy and bill and in-office infusion get discussed as though they were two separate decisions. They are not. In-office infusion is the clinical program: the chairs, the nursing staff, the administration workflow. Buy and bill is the acquisition and reimbursement model that program runs on. A practice standing up infusion will use buy and bill by default, because the drugs in question are provider administered.
This is also why the two rise and fall together. Every argument for buy and bill is an argument for keeping the infusion in your office, and every pressure on buy and bill is a pressure pushing your patients somewhere else: to a hospital outpatient chair, to home infusion, or to a pharmacy that ships the drug to you.
The alternative to buy and bill is not a different billing method. It is a different site of care, with a different care team, and usually without you.
A practice using buy and bill can confirm a drug's pedigree, maintain product integrity from delivery through administration, and control the conditions of administration. That control also extends to acquisition price, which matters in therapeutic categories where ASP margins have been compressing.
Drugs delivered by an external pharmacy often arrive without the manufacturer's original labeling, because they have been compounded or repackaged. That raises questions about integrity and authenticity that the administering practice cannot answer. If the product does not match what was specified, it may have to be destroyed, which creates waste the practice absorbs.
Because the practice bills the payer directly for the drug, the reimbursement lands with the practice rather than with an external pharmacy. Practices typically acquire at Average Sales Price and are reimbursed at a markup above it. When a specialty pharmacy stores and dispenses the product instead, it captures that margin.
Buy and bill carries real upfront financial risk. The practice pays for inventory before it is reimbursed, and someone has to manage that inventory properly. It also assumes the practice has the operational infrastructure to handle benefits investigation, prior authorization and claims, which is a meaningful ask for a small team already running a clinic.
The larger problem is margin. Medicare Part B reimburses at ASP plus a statutory 6%, which lands closer to ASP plus 4.3% after sequestration. Commercial payers negotiate their own rates and pay more, but the benefit is distributed very unevenly. Commercial markups average 13% for office-based practices and reach 148% for hospital-based clinicians.6
That gap is a consolidation engine. Large health systems, especially those with 340B eligibility, can buy below ASP and earn on both Medicare and commercial patients. Smaller independent practices often buy above ASP, which leaves them with negative margins on Medicare patients and thin margins on commercial ones.6 For an independent practice, this makes buy and bill harder to sustain on drug margin alone, and makes the clinical and operational side of the program, the part that determines whether patients actually stay, matter more rather than less.
Meanwhile, payers and pharmacy benefit managers have been steering volume toward their own specialty pharmacy networks as a cost-containment strategy. Practices want to keep control of the drug. Payers want the drug to come from somewhere they control. That tension is the whole story of the bagging models below.
Specialty pharmacies that dispense for oncology, hemophilia, multiple sclerosis and other complex conditions generally use white or brown bagging. In both, the manufacturer ships to an external specialty pharmacy, which then sends the product onward. Clear bagging is different: it involves a health system's own internal pharmacy and is not an external delivery model.
A specialty pharmacy ships the patient's prescription to the provider's office, where the practice stores it until administration. This often means a separate refrigerator and a separate inventory for patient-specific product. White-bagged medications are billed through the pharmacy benefit, Part D for Medicare, rather than the medical benefit, so the practice does not capture the drug reimbursement it would have under buy and bill.
The clinical problems are worse than the financial ones. An external pharmacy sitting outside the clinical workflow cannot reliably tell whether the patient is still on therapy, has had an adverse reaction, or is due for a refill before the next dose auto-ships. When a dose changes at the last minute, pre-shipped product may be unusable, which means waste, a rescheduled appointment, and a delay in treatment.
Provider organizations have pushed back. The American Medical Association, the American Society of Clinical Oncology and the American Society of Health-System Pharmacists have all raised concerns about patient safety, treatment delays and medication waste under white bagging mandates.1,2 As of 2025, 12 states have enacted legislation banning or restricting mandatory white bagging, with bills introduced in more than 30 states since 2021.1,2 The practice is widespread enough to matter: in 2022, 27% of oncology therapy products administered in physician offices under commercial insurance were subject to white bagging policies.3
The patient obtains the drug, stores it, and transports it to the office for administration. Nobody can verify that it was held at the correct temperature or handled properly in transit, so there is no chain of custody worth the name. Most hospitals and health systems have banned brown bagging outright, and ASCO has formally opposed it.3
The practice's own dispensing team prepares the prescription internally and delivers it to the point of care. Because everything stays inside the organization, clear bagging offers tighter chain of custody than white or brown bagging, real-time coordination between the dispensing team and clinical staff, and less waste when a dose changes. The catch is that clear bagging as usually described depends on a health-system-owned pharmacy, which most independent practices do not have.
For independent practices in neurology, rheumatology, gastroenterology, oncology and dermatology, the bagging models set up a narrow choice. White and brown bagging pull both control and reimbursement out of the practice. Clear bagging assumes an internal pharmacy the practice does not own. Buy and bill keeps both, but only works if the practice can carry the inventory risk and the administrative load.
So the question is not whether buy and bill is a good model. It is whether your practice has the infrastructure to run it well. Benefits investigation, prior authorization, payer intelligence, procurement on the correct NDC, claim reconciliation and DSCSA compliance are all solvable. They are just not solvable by adding them to the workload of a clinic that is already full.
That is the case for running buy and bill inside a supported in-office infusion program rather than building the whole apparatus yourself. The practice keeps the drug, the patient and the clinical relationship. The operational weight sits with a partner.
Neurology is where the site-of-care question has the sharpest clinical edge, because the therapies are not interchangeable and the patients are on them for years.
IVIG products are not therapeutically interchangeable, and under white bagging a brand substitution can happen without the prescriber's consent. Some infused neurology therapies cannot be given at home at all: natalizumab's REMS requirements make home administration non-compliant. When an infusion happens somewhere else, reactions occur where the ordering physician cannot observe or respond, and home infusion carries roughly 25% higher odds of an emergency department visit or admission.8
Keeping the infusion in the office also collapses two appointments into one. The clinical assessment and the infusion happen at the same visit, so strength testing, symptom review and dose decisions all occur at the point of care. That shows up in the persistence data. Real-world adherence across infusion DMTs reaches 96.6%, the highest of any DMT route,9 and 12-month discontinuation for in-office ocrelizumab is 8% against 43% for injectable DMTs.10
The cost comparison points the same direction. The same infusion delivered in a hospital outpatient setting costs 42% to 104% more than in a physician office, with no difference in outcome.11
Two federal laws, the Inflation Reduction Act and the One Big Beautiful Bill Act, are making self-administered specialty drugs more expensive and harder to access, while office-based infusion stays comparatively stable. Most neurology infusion biologics are shielded from Medicare price negotiation into 2029 through 2033, and IVIG is permanently excluded as a plasma-derived product. On the pharmacy side, Part D deductibles and coinsurance are climbing and formularies are shrinking, and more than half of high-cost self-administered prescriptions now go unfilled at the pharmacy.12
ASP-based reimbursement, meanwhile, has been left essentially untouched by the new rules. For a neurology practice weighing where infusion should happen, that is a policy tailwind with a known expiry date.
See how in-office infusion works for neurology practices
Buy and bill covers provider-administered drugs. It does not cover oral oncolytics, self-administered biologics and other specialty medications that patients currently collect from an external pharmacy. Medically integrated dispensing brings those in-house, under the pharmacy benefit rather than the medical benefit, and applies the same logic of control and coordination to drugs that do not require provider administration. NCODA reports that integrated dispensing networks see under 5% prescription abandonment against a 20% industry average, fill in under two days rather than 14 to 30, and hold adherence above 90% against a 60% standard.4
For a practice already running infusion, dispensing is a second program worth looking at once the first one is performing.
Moving to buy and bill takes planning and dedicated staff time. Four things need an owner before you start.
Insurance approvals. Someone needs to own benefits investigation and prior authorization for the specific therapies you intend to cover. Part time does not work here.
Clinical staffing. You need enough licensed clinicians to administer the products and to run patient support.
Inventory management. You need a system that tracks inventory, volume and lead time by drug, and ties it to the patients who need it.
DSCSA compliance. The Drug Supply Chain Security Act sets federal requirements for prescription drug identification, tracing and verification. Whether you are managing buy and bill inventory or dispensing, you need trading partner verification, product tracing and verification capability in place.
If your practice is small, be honest about your team's existing workload before you add this to it. Training matters, but capacity matters more.
Running buy and bill well requires technology and operational support that most practices are not resourced to build: inventory tracking with lot and serial number management, DSCSA compliance, prior authorization workflows, EHR and practice management integration, and coordination between clinical and pharmacy teams. ASHP surveys of health-system specialty pharmacies name restricted access to payer networks, hiring and retaining qualified staff, and managing workflows across multiple stakeholders as the recurring operational obstacles.7 Turnaround times track closely with how well the technology is integrated.
OnePulse Connect Infusion brings in-office infusion services to your practice so patients receive treatment at their trusted site of care. The program includes consistent, high-touch support from our nurses, patient education, and the ongoing communication that keeps patients on therapy. Benefits investigation, prior authorization, payer intelligence and claim reconciliation run on our side rather than your staff's desk, and every engagement starts with a practice-specific proforma so you see your own economics before anything is proposed. Learn more.
OnePulse Connect Buy and Bill is a medication management solution for practices that want tighter control of the drug lifecycle. Users assign purchase orders to specific patients and track items by lot and serial number, with integrations for practice management, suppliers and financial software.
A turnkey program for practices adding in-office dispensing alongside infusion. Learn more.
Under buy and bill, the provider purchases the drug from a distributor, administers it, and bills the payer under the medical benefit. Under specialty pharmacy fulfillment, an external pharmacy fills the prescription and ships it either to the provider (white bagging) or to the patient (brown bagging). The difference is who controls the drug and who captures the reimbursement. Under buy and bill, the practice keeps both.
The practice purchases the drug, administers it, then submits a claim to the patient's insurer. Medicare Part B reimburses at Average Sales Price plus a statutory 6%, which lands nearer ASP plus 4.3% once sequestration is applied.5 Commercial payers negotiate independently and their rates vary considerably. The practice bills separately for the administration service under the relevant injection or infusion CPT codes.
Commercial markups typically run 6% to 18% depending on the drug, the payer contract and the practice's purchasing power, but the average conceals a wide spread: 13% for office-based practices against 148% for hospital-based clinicians.6 That gap is driven largely by 340B eligibility and large-system purchasing power. Independent practices without those advantages increasingly find Medicare patients unprofitable to treat on drug margin alone.
In-office infusion is the clinical program: the infusion suite, the nursing staff, the administration infrastructure. Buy and bill is the acquisition and reimbursement model used inside it. A practice starting an infusion program will typically use buy and bill to purchase infusible drugs from distributors and bill payers after administration. In-office infusion is how you deliver the therapy. Buy and bill is how you acquire the drug and get paid for it.
White bagging is when a specialty pharmacy ships a patient's medication to the provider's office for administration. States are restricting mandatory white bagging over patient safety, treatment delays, medication waste and loss of provider control. The AMA, ASCO and ASHP have all opposed mandates, and as of 2025, 12 states have enacted legislation addressing them.1,2
The practice usually cannot substitute from its own inventory, because the product is patient specific and billed through the external pharmacy. That means rescheduling the patient, reordering, and delaying treatment by days or weeks. The practice also cannot bill for the wasted product, since it did not purchase it. Under buy and bill the practice holds inventory and can adjust immediately.
The Drug Supply Chain Security Act sets federal requirements for prescription drug identification, tracing and verification across the supply chain. Practices using buy and bill must meet DSCSA expectations for dispensers, including trading partner verification and product tracing. The same requirements apply to dispensing programs.
Oncology, rheumatology, neurology, gastroenterology, dermatology and urology. These specialties manage complex therapies that often require provider administration, including biologics, immunomodulators and infusion-based treatments. The model works best for practices with enough patient volume to justify inventory investment and dedicated staff for benefits investigation and billing.
Yes, and the two are complementary. Buy and bill covers provider-administered drugs. Medically integrated dispensing covers oral and self-administered specialty medications under the pharmacy benefit. Practices commonly pair both with an in-office infusion suite.
Yes. Practices with dispensing programs can bill for comprehensive medication management using CPT codes 99605 to 99607 when a pharmacist provides face-to-face assessment, medication therapy review and care plan development. These are separately reimbursable. Depending on payer and state rules, practices may also bill for medication administration, patient education and care coordination.
Elevate Health Technologies is committed to making healthcare better for everyone. We collaborate with healthcare providers, patients, pharmaceutical manufacturers, and payers to deliver personalized solutions and innovative technologies that truly make a difference. OnePulse Connect empowers healthcare practices by optimizing efficiency and streamlining care, whether through buy-and-bill management, inventory tracking, medically integrated dispensing, or in-office infusion services. Our tailored approach delivers deep data insights, advanced analytics, and dynamic patient engagement platforms. Together, we move as One Pulse, driving smarter, faster, and more connected health technologies for improved outcomes and better patient experiences.
Visit www.elevateht.com or follow us on LinkedIn.
Copyright © 2026 Elevate Health Technologies
